MedTrace Logo

Real-World Evaluation Screening Study and Registry of Dyskinesia in Patients Taking Antipsychotic Agents

NCT03062033 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 70

Last updated 2017-11-22

No results posted yet for this study

Summary

Prospective study to quantify the prevalence of possible tardive dyskinesia (TD) in outpatient psychiatry practices in the United States (US), as well as to describe the associated disease burden in a cohort of patients with one or more psychiatric disorders and a cumulative lifetime exposure to antipsychotic medication of three months or more.

Conditions

  • Tardive Dyskinesia

Sponsors & Collaborators

  • Evidera

    collaborator INDUSTRY

  • Neurocrine Biosciences

    lead INDUSTRY

Principal Investigators

  • Chris O'Brien, MD · Chief Medical Officer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-04-04
Primary Completion
2018-08-31
Completion
2018-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03062033 on ClinicalTrials.gov